Segment Information - Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Net sales	$ 10,622	$ 3,355	$ 16,479	$ 11,035
Gross profit	8,311	2,322	11,486	7,273
Direct expenses	45,409	19,544	121,799	64,146
Segment contribution	(37,098)	(17,222)	(110,313)	(56,873)
Indirect expenses	(47,996)	(12,416)	(16,205)	106,107
Income loss from operations	10,898	(4,806)	(94,108)	(162,980)
Components of other
Change in fair value of contingent consideration liability	(48,549)	(142,599)	(17,845)	(26,136)
Impairment of acquired intangibles		129,400		129,400
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	22,690	10,913	61,082	38,185
Segment contribution	(22,690)	(10,913)	(61,082)	(38,185)
Biobanking
Segment Reporting Information [Line Items]
Net sales	1,343	1,399	4,204	4,213
Gross profit	420	710	1,986	2,445
Direct expenses	505	806	1,499	1,943
Segment contribution	(85)	(96)	487	502
Degenerative Disease
Segment Reporting Information [Line Items]
Net sales	9,279	1,956	12,275	6,822
Gross profit	7,891	1,612	9,500	4,828
Direct expenses	2,601	2,177	6,765	8,635
Segment contribution	5,290	(565)	2,735	(3,807)
Other
Segment Reporting Information [Line Items]
Direct expenses	19,613	5,648	52,453	15,383
Segment contribution	(19,613)	(5,648)	(52,453)	(15,383)
Indirect expenses	(47,996)	(12,416)	(16,205)	106,107
Components of other
Change in fair value of contingent consideration liability	(48,549)	(142,599)	(17,845)	(26,136)
Amortization	553	783	1,640	2,843
Total other	$ (47,996)	(12,416)	$ (16,205)	106,107
Impairment of acquired intangibles		$ 129,400		$ 129,400